Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles (Q34006864)

30 July 2017

1 reference

title

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles (English)

1 reference

30 July 2017

Nasrallah HA

1

1 reference

PubMed ID

17848919

30 July 2017

language of work or name

English

0 references

publication date

11 September 2007

1 reference

30 July 2017

1 reference

30 July 2017

13

1 reference

30 July 2017

27-35

1 reference

30 July 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.mp.4002066

30 July 2017

0 references

cites work

The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Causes of the excess mortality of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Comparison of the in-vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

The place of partial agonism in psychiatry: recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Partial agonism and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Muscarinic receptors in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

The safety of newly approved medicines: do recent market removals mean there is a problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

A review of the effect of atypical antipsychotics on weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Weight change with atypical antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Differential metabolic effects of antipsychotic treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Weight decline in patients switching from olanzapine to quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Bodyweight gain with atypical antipsychotics. A comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Genetic variants of the serotonin system and weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Schizophrenia and diabetes: epidemiological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Diabetes and schizophrenia 2005: are we any closer to understanding the link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Olanzapine-associated diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Olanzapine-induced glucose dysregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Prevalence of the metabolic syndrome in veterans with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Therapeutic roles of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Atypical antipsychotics and weight gain--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

7 January 2021

Hypersalivation induced by olanzapine with fluvoxamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

7 January 2021

Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D2 Receptor Antagonist

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

7 January 2021

Metabolic findings from the CATIE trial and their relation to tolerability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

7 January 2021

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

7 January 2021

759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

7 January 2021

Undiagnosed hyperglycemia in patients treated with atypical antipsychotics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

7 January 2021

Novel antipsychotics and new onset diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

7 January 2021

Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002066

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4002066

1 reference

30 July 2017

1 reference

PubMed ID

17848919